A Review of Recent Advances in the Anticancer Mechanisms of Activity of Novel Thiazoles and 4-Thiazolidinones/Thiazolidinediones (2021–2025)
Molecules · 2026
DOI: 10.3390/molecules31091444 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecules, 2026. Verfasst von Rostyslav Dudchak und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Synthesis and Technology of Drugs, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089 Bialystok, Poland. Hauptthemen laut MEDLINE: Antineoplastic Agents, Thiazolidines, Thiazolidinediones, Drug Design. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 132 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Ukraine, Medical University of Białystok.
Abstract (Originalsprache)
With global cancer cases projected to reach 35 million by 2050 and drug resistance to existing chemotherapeutic drugs remaining a significant threat in cancer therapy, accounting for up to 90% of chemotherapy failures, the search for novel anticancer compounds continues to be increasingly important. This systematic review (2021–2025) examined the role of thiazoles and 4-thiazolidinones/thiazolidinediones as popular scaffolds in existing anticancer drug design. While researchers continue to focus on well-established molecular targets, such as EGFR, VEGFR-2, and tubulin, there is a notable difference regarding other preferred choices for thiazoles and 4-thiazolidinones/thiazolidinediones. Among analyzed mechanisms of anticancer activity notably favored for thiazoles was the inhibition of serine/threonine protein kinases (CDK-2, BRAFV600E), while for 4-thiazolidinones/thiazolidinediones more studied were ROS generation and PPARγ activation. Furthermore, less-researched mechanisms of anticancer activity with no FDA-approved drugs such as PTP1B, SIRT2, PKM2, eIF4E, CA XI and XII inhibition for thiazole derivatives and pan-PIM kinase and BAG3 protein inhibition for 4-thiazolidinones/thiazolidinediones were evaluated as well. Notable was the popularity of the multi-targeting approach for modern drug design, with ~30% reporting two or more targets for their compounds. Despite these advancements, the review identified critical gaps in ADMET evaluations, safety analyzing against normal human cells and the lack of mechanistic studies connecting the targeted protein and the compounds anticancer effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Synthesis and Technology of Drugs, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089 Bialystok, Poland.
- Department of Biotechnology, Faculty of Pharmacy, Medical University of Bialystok, Jana Kilińskiego 1, 15-089 Bialystok, Poland.
- Department of Pharmaceutical, Organic and Bioorganic Chemistry, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine.
- Molecular Design Center, Danylo Halytsky Lviv National Medical University, Pekarska 69, 79010 Lviv, Ukraine.
- Department of Biotechnology and Cell Biology, University of Information Technology and Management in Rzeszow, St. Sucharskiego 2, 35-225 Rzeszow, Poland.
ORCID-Profile: Krzysztof Bielawski, Roman Lesyk
Förderung
- National Research Foundation of Ukraine
- Medical University of Białystok
Zitieren
APA
Dudchak, R., Podolak, M., Bielawska, A., Bielawski, K., & Lesyk, R. (2026). A Review of Recent Advances in the Anticancer Mechanisms of Activity of Novel Thiazoles and 4-Thiazolidinones/Thiazolidinediones (2021–2025). Molecules. https://doi.org/10.3390/molecules31091444
Vancouver
Dudchak R, Podolak M, Bielawska A, Bielawski K, Lesyk R. A Review of Recent Advances in the Anticancer Mechanisms of Activity of Novel Thiazoles and 4-Thiazolidinones/Thiazolidinediones (2021–2025). Molecules. 2026. doi:10.3390/molecules31091444
BibTeX
@article{Dudchak2026,
author = {Dudchak, Rostyslav and Podolak, Magdalena and Bielawska, Anna and Bielawski, Krzysztof and Lesyk, Roman},
title = {A Review of Recent Advances in the Anticancer Mechanisms of Activity of Novel Thiazoles and 4-Thiazolidinones/Thiazolidinediones (2021–2025)},
journal = {Molecules},
year = {2026},
doi = {10.3390/molecules31091444}
}
EUVIMED